Integrated microfluidic device for rapid and accurate point-of-care detection of high-risk HPV16 and HPV18

to 1 copy per µL. A clinical evaluation of 50 cervical swab samples yielded a sensitivity of 96.8% and a specificity of 100% compared to qPCR, with positive and negative predictive values of 100% and 94.7%, respectively. The platform's portability, low cost, and minimal user intervention make it an ideal solution for decentralized settings, offering a transformative approach to early HPV screening and cervical cancer prevention in resource-limited environments.